Skip to content

Study · Non-randomized trial · n = 20 · 2006

4 results

Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH.

Correa-Silva SR, Nascif SO, Lengyel AM

Pituitary1 Jan 2006Cited by 12 (Europe PMC)

PMID16832586 (opens in a new tab)DOI10.1007/s11102-006-9149-8 (opens in a new tab)PepBankPUB-16832586
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with Cushing's disease, GHRP‑6-induced GH release was lower than in controls.

    In plain wordsIn people with Cushing's disease, GHRP‑6 raised growth hormone less than in controls.

    Peptide
    GHRP-6
    Outcome
    DecreasePeak GH response to GHRP-6 in Cushing's disease versus controls
    Study

    n = 20

    Comparator
    Controls
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kgAs given in this study (human).

    Measurements

    Peak GH
    2.7 microg/L
    Cushing's disease
    Peak GH
    22.9 microg/L
    controls

    Source sentences

    Summary
    In CD ghrelin-induced GH (microg/L; mean +/- SE) release (peak: 7.2+/-3.0) was higher than seen with GHRP-6 (2.7+/-1.0) and GHRH (0.7+/-0.2), but lower than in controls (ghrelin: 58.3+/-12.1; GHRP-6: 22.9+/-4.8; GHRH: 11.3+/-3.7).
    1 context sentence
    Summary · context
    Ten patients with CD (BMI 26.9+/-1.0 kg/m(2)) and ten controls (BMI 24.4+/-1.1 kg/m(2)) received ghrelin (1 microg/kg), GHRP-6 (1 microg/kg) and GHRH (100 microg) separately.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with Cushing's disease, GHRP‑6-induced GH release was lower than ghrelin-induced GH release.

    In plain wordsIn people with Cushing's disease, GHRP‑6 raised growth hormone less than ghrelin did.

    Peptide
    GHRP-6
    Outcome
    DecreasePeak GH response to GHRP-6 compared with ghrelin in Cushing's disease
    Study

    n = 20

    Comparator
    Ghrelin
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kgAs given in this study (human).

    Measurements

    Peak GH
    2.7 microg/L
    GHRP-6, Cushing's disease
    Peak GH
    7.2 microg/L
    ghrelin, Cushing's disease

    Source sentences

    Summary
    In CD ghrelin-induced GH (microg/L; mean +/- SE) release (peak: 7.2+/-3.0) was higher than seen with GHRP-6 (2.7+/-1.0) and GHRH (0.7+/-0.2), but lower than in controls (ghrelin: 58.3+/-12.1; GHRP-6: 22.9+/-4.8; GHRH: 11.3+/-3.7).
    1 context sentence
    Summary · context
    Ten patients with CD (BMI 26.9+/-1.0 kg/m(2)) and ten controls (BMI 24.4+/-1.1 kg/m(2)) received ghrelin (1 microg/kg), GHRP-6 (1 microg/kg) and GHRH (100 microg) separately.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with Cushing's disease, the ACTH response to GHRP‑6 was enhanced compared with controls.

    In plain wordsIn people with Cushing's disease, GHRP‑6 raised ACTH more than in controls.

    Peptide
    GHRP-6
    Outcome
    IncreaseACTH response to GHRP-6 in Cushing's disease versus controls
    Study

    n = 20

    Comparator
    Controls
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kgAs given in this study (human).

    Measurements

    ACTH response
    185 pg/mL
    Cushing's disease
    ACTH response
    23.6 pg/mL
    controls

    Source sentences

    Summary
    In CD these responses (ghrelin: 192+/-43; GHRP-6: 185+/-56) were similar, and enhanced compared to controls.
    2 context sentences
    Summary · context
    In controls ACTH (pg/mL) release after ghrelin (79.2+/-26.8) was higher than after GHRP-6 (23.6+/-5.7).
    Summary · context
    Ten patients with CD (BMI 26.9+/-1.0 kg/m(2)) and ten controls (BMI 24.4+/-1.1 kg/m(2)) received ghrelin (1 microg/kg), GHRP-6 (1 microg/kg) and GHRH (100 microg) separately.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with Cushing's disease, the cortisol response to GHRP‑6 was enhanced compared with controls.

    In plain wordsIn people with Cushing's disease, GHRP‑6 raised cortisol more than in controls.

    Peptide
    GHRP-6
    Outcome
    IncreaseCortisol response to GHRP-6 in Cushing's disease versus controls
    Study

    n = 20

    Comparator
    Controls
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1 microg/kgAs given in this study (human).

    Source sentences

    Summary
    The same was observed with cortisol.
    2 context sentences
    Summary · context
    In CD these responses (ghrelin: 192+/-43; GHRP-6: 185+/-56) were similar, and enhanced compared to controls.
    Summary · context
    Ten patients with CD (BMI 26.9+/-1.0 kg/m(2)) and ten controls (BMI 24.4+/-1.1 kg/m(2)) received ghrelin (1 microg/kg), GHRP-6 (1 microg/kg) and GHRH (100 microg) separately.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:35 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    12 Oct 2026, 12:58 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.